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pacemakerTable 1
General features of patients at baseline.
Parameters NIPS EPS P value
N 52 60 –
Age (years) 64.5 ± 14.4 69.8 ± 18.3 0.0948
Body mass index, kg/m2 29.7 ± 4.2 30.6 ± 5.1 0.3148
Male sex (%) 35 (67%) 39 (65%) 0.8433
White ethnicity (%) 33 (63%) 36 (60%) 0.8457
Hypertension 40 (77%) 42 (70%) 0.5217
Type 2 diabetes mellitus 30 (58%) 44 (73%) 0.1094
Coronary artery disease 42 (81%) 45 (75%) 0.5028
Echocardiographic parameters
LV ejection fraction (Simpson), % 38.5 ± 7.2 41.0 ± 9.1 0.1136
LV mass index, g/m2 155.1 ± 18.2 147.4 ± 19.3 0.0351
LV internal dimension at the end
of diastole, mm
62.4 ± 10.0 60.8 ± 9.3 0.3825
LV internal dimension at the end
of systole, mm
50.5 ± 12.1 53.2 ± 13.8 0.2768
Mean 24-hour ABPM, mmHg 128 ± 8/
81 ± 4
126 ± 7/
80 ± 6
0.3509
0.3946
Antihypertensive
β-blocker 52 (100%) 60 (100%) 1.0000
ACE-inhibitors/ARB 52 (100%) 60 (100%) 1.0000
Spironolactone 52 (100%) 60 (100%) 1.0000
Diuretics 30 (58%) 42 (60%) 0.8534
DHP calcium channel blockers 10 (19%) 14 (23%) 0.6498
Values are presented as mean ± SD or %; ABPM, ambulatory blood pressure measure-
ments; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DHP,
dihydropyridine; EPS, electrophysiological study; LV, left ventricular; N, number of pa-
tients; NIPS, non-invasive electrophysiological study.Keywords:
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It is well established in the literature the relationship between struc-
tural heart disease and the occurrence of sudden cardiac death (SCD). In
more than 70% of cases, the underlying heart disease is myocardial is-
chemia. The pathophysiology results from the interaction between the
generator event and electrical instability inducing ventricular tachycar-
dia, which degenerates into ventricular ﬁbrillation. The high mortality
resulting from these recurring ventricular tachyarrhythmias stimulated
the development of various therapies with the purpose of preventing
SCD, among which the surgical approach or radiofrequency ablation or
resection aiming the elimination of arrhythmogenic focus and electrical
treatment for cardiac stimulation artiﬁcial implantable cardioverter-
deﬁbrillator (ICD) and cardiac resynchronization therapy (CRT) [1].
The ICDwas introduced in clinical practice in patients surviving a cardi-
ac arrest due to ventricular ﬁbrillation or sustained ventricular tachycar-
dia hemodynamically unstable and associated with structural heart
disease, so for secondary prevention of sudden cardiac death [2,3,4,5,
6]. Several DDD pacemaker patients have structural heart disease with
concentric and/or eccentric hypertrophy, and moderate systolic dys-
function presenting episodes of non-sustained ventricular tachycardia
spontaneous recorded by the device, without ICD implantation
indication.
In this study, we evaluated 112 patients with DDD pacemaker (St.
JudeMedical, St. Paul, Minnesota, USA), concentric and/or eccentric hy-
pertrophy, and moderate systolic dysfunction presenting episodes of
non-sustained ventricular tachycardia spontaneous recorded by the de-
vice, without ICD implantation indication, age between 18 and 80 years,
and patients who provided documentation not presenting cardiac is-
chemia evidenced by myocardial scintigraphy at rest and during stress,
echocardiography during stress or coronary angiography. We divided
the patients into 2 groups: 52 patients underwent non-invasive pro-
grammed stimulation (NIPS) by the pacemaker, and 60 patients were
submitted to electrophysiological study (EPS). The baseline features of
both groups are demonstrated in Table 1. All patients underwent NIPS
or EPS with three extra-stimuli coupled to a programmed cycle length
of 430ms (140 ppm). The results were expressed as themean and stan-
dard deviation (mean± SD) of themean in the case of normal distribu-
tion and as the median with inter-quartile range otherwise. Statistical
tests were all two sided. Comparisons between two-paired values
were performed by the paired t-test in case of Gaussian distributionhttp://dx.doi.org/10.1016/j.ijcme.2016.10.001
2214-7624/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access articlor, alternatively, by the Wilcoxon test. All statistical analysis was per-
formed using the program Graphpad Prism v 7.0 (Graphpad software,
La Jolla, CA, USA).
The mean extra-stimuli sequence to induce ventricular tachycardia
was a programmed cycle length of 430 ms (S1S1) composed by 8
extra-stimuli (S1 count), followed by S1S2 = 275 ± 22 ms, S2S3 =
240 ± 15 ms and S3S4 = 220 ± 9 ms in the NIPS group (P b 0.0001
for all the extra-stimuli comparisons into the same group), and
S1S2 = 300 ± 16 ms, S2S3 = 270 ± 24 ms and S3S4 = 230 ± 11 ms
in the EPS group (P b 0.0001 for all the extra-stimuli comparisons into
the same group). All the comparison of the same extra- stimulus be-
tween groups were signiﬁcant, (P b 0.0001 for all of them), as shown
in Fig. 1. The incidence of ventricular tachycardia/ﬁbrillation induction
was higher in EPS group (52%) than in NIPS group (29%), P = 0.0206,
as shown in Fig. 2.
Our results show that EPS is more effective to induce VT/VF than by
NIPS protocol in the same type of population. The number of subjects
who developed VT/VF was 23% higher in the group submitted to EPS.Conﬂict of interest
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ﬂict of interest.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Mean extra-stimuli sequence to induce ventricular tachycardia was a programmed
cycle length of 430 ms (S1S1) composed by 8 extra-stimuli (S1 count), followed by S1S2,
S2S3 and S3S4 in the NIPS (n= 52) and EPS (n= 60) group. *P b 0.0001 for comparisons
of the same extra-stimulus between groups; EPS, electrophysiological study; NIPS, non-
invasive programmed stimulation.
Fig. 2. Incidence of ventricular tachycardia/ﬁbrillation induction in EPS (52%) and NIPS
(29%) group; EPS, electrophysiological study; NIPS, non-invasive programmed
stimulation; VT, ventricular tachycardia; VF, ventricular ﬁbrillation.
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